SUMMARY Dopexamine, a new compound with postjunctional dopamine receptor activating and beta adrenoceptor agonist properties, was given to 10 patients with chronic heart failure at diagnostic cardiac catheterisation to investigate its acute haemodynamic and metabolic effects. The drug was administered by intravenous infusion in three incremental doses and produced significant dose related increases in cardiac index, stroke volume index, and heart rate and falls in systemic vascular resistance and left ventricular end diastolic pressure; aortic and pulmonary artery pressures were unchanged. Isovolumic phase (max dP/dt and KVmax) and ejection phase (peak aortic blood velocity, maximum acceleration of blood, and maximum rate of change of power with time during ejection) indices of myocardial contractility were all increased by dopexamine but these changes were hard to interpret in the presence of an increase in heart rate. Myocardial efficiency and ejection fraction were both increased and left ventricular end diastolic and end systolic volumes fell. These largely beneficial changes were achieved without a statistically significant increase in myocardial oxygen consumption or disturbance of myocardial metabolic function. Dopexamine was well tolerated but tremor was reported by two patients at the intermediate dose and mild chest pain by two patients at the high dose.
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Dopamine is well established in the management of acute or acute on chronic heart failure. 2 The clinical value of dopamine, however, is often limited by alpha adrenoceptor mediated peripheral constriction,34 which increases the load faced by the left ventricle during ejection. Consequently myocardial oxygen demand increases and myocardial ischaemia may be induced in patients with coronary artery disease.5 Dopexamine (Fisons Pharmaceutical Division) is a recently synthesised compound which is structurally related to dopamine (Fig. 1) . Like dopamine it can only be administered intravenously. In vitro and in vivo animal experiments show that the drug activates postjunctional dopamine receptors (equipotently with dopamine), has substantial beta2 adrenoceptor agonist activity, has no beta, adrenoceptor agonist activity, and, unlike dopamine, is inactive at Requests for reprints to Dr J R Dawson, Department of Cardiology, St Thomas' Hospital, London SE1 7EH.
Accepted for publication 21 May 1985 the alpha adrenoceptors.67 This pharmacological profile suggests that dopexamine will produce haemodynamic improvement in patients with heart failure and because of its theoretical superiority to dopamine is worthy of evaluation. The haemodynamic and metabolic effects of dopexamine were evaluated in 10 patients with severe chronic heart failure. 
PATIENTS
Ten patients (nine men and one women, mean age 54 (range 44-69)) with chronic heart failure undergoing diagnostic cardiac catheterisation participated in the study. Each patient gave written consent and the study protocol was approved by the hospital ethics committee. All patients were severely limited by dyspnoea (class 3, New York Heart Association), had radiographic evidence of cardiomegaly and pulmonary venous congestion, and required large maintenance doses of diuretics. Five 
INDICES OF CONTRACTILITY
The data for the various indices of contractility are shown in Fig. 3 . The two isovolumic phase indices of myocardial contractility were both significantly increased during dopexamine infusion. dP/dt max rose from 646(50) mm Hg/s at control to 847(86) mm Hg/s at the high dose (p < 0 001). Similarly KVmax was increased from 65(4)s to 88(12)s (p<0-01).
Technically satisfactory velocity signals were obtained in-seven of the-10-patients studied. The ejection phase indices of contractility were all significantly increased by dopexamine administration (p<0-01). Peak aortic blood velocity increased from a control value of 30(5) cm/s to 58 (13) cm/s at the high dose level. Maximum acceleration of blood during ejection rose from 520(123) cm/s2 to 965(257) cm/s2. The maximum rate of change of power with time (dPower/dt) was increased from 38(7) watts/s to 72 (13) watts/s at the high dose. Fig. 4 illustrates the relation between two of these indices of contractility (max dP/dt and KVmax) and changes in heart rate. In 4 Relation between change in heart in max dP/dt (a) and change in KVmax patients at low (I pg/kg/min), intermedia and high (6 resistance suggest that dopexamine has relatively little action on systemic capacitance vessels or on the a net extractor of pulmonary circulation and that its principal site of on but another vasodilator action is the systemic arterial system )pathy changed (that is reduction of afterload). .e to being a net Although all of the isovolumic and ejection phase iine infusion.
indices of myocardial contractility were significantly increased by dopexamine, these findings must be interpreted with caution. The contractile state of the 11 tolerated by all ventricle is modulated by preload, afterload, and ,g/min) dose two heart rate.23 All of these changed during the study emulousness at a and such changes may therefore have been haemodynamic responsible for the apparent increase in the level of give these two myocardial contractility. It is instructive to compare ise. Of the eight the results of this study with those of a previous Dse, two patients study performed in our laboratory on the haemoiisease) reported dynamic effects of the vasodilator sodium nitro- prusside in a similar group of patients with chronic heart failure.24 Sodium nitroprusside produced changes in preload and afterload which resembled those produced by dopexamine, but in contrast heart rate was not altered and the isovolumic phase indices of contractility maximum dP-dt and KVmax were unchanged. It could be argued that the increase in the indices of contractility observed in our patients treated with dopexamine were secondary to an increase in heart rate. Analysis of individual responses which compared changes in heart rate with changes in the isovolumic phase indices seems to confirm this assertion with respect to maximum dP/dt (Fig. 4) . There were several patients, however, in whom KVmax rose substantially at the low and intermediate doses without concomitant increases in heart rate (Fig. 4) , a finding that may cautiously be interpreted as evidence that dopexamine has some direct positive inotropic action.
The striking increases in cardiac ouput observed in all patients were mediated through both an increase in stroke volume and an increase in heart rate. Inspection of Fig. 2 suggests that at the low dose the effect of a stroke volume increase predominated but at the intermediate and high doses increased heart rate was an important contributory factor to the improvement in cardiac output. The increase in heart rate produced by dopexamine may be due either to a direct positive chronotropic action (beta1 adrenoceptor mediated) or to a reflex tachycardia secondary to peripheral vasodilatation caused by the drug. We suggest that it is the former because when the "pure" vasodilator sodium nitroprusside was given to patients with heart failure there was a similar fall in systemic vascular resistance to that produced by dopexamine without a significant alteration in heart rate. 24 Administration of a drug with a positive chronotropic action to patients with coronary artery disease is potentially deleterious because myocardial ischaemia may be induced either by increased myocardial oxygen consumption25 or by a reduction in coronary artery diastolic filling time.
The highly significant haemodynamic changes observed in our patients were associated with only a small and statistically insignificant rise in myocardial oxygen consumption. Myocardial oxygen consumption is determined by heart rate, the contractile state of the ventricle, and ventricular load.25 In our patients the positive chronotropic and possible positive inotropic effects of dopexamine would both be expected to increase myocardial oxygen consumption, but this effect has in the main been offset by other drug induced reductions in components of left ventricular load such as systemic vascular resistance and left ventricular volume and end diastolic pressure.
The effect of dopexamine on myocardial energetics can be examined by estimating myocardial In most patients the pattem of myocardial substrate utilisation when control measurements were obtained was similar to results reported in the normal heart,27 but two patients (one with coronary artery disease and one with congestive cardiomyopathy) were net myocardial producers of lactate at rest and this indicates some degree of anaerobic metabolism. Dopexamine seemed to have no important actions on myocardial metabolic function; it had little effect on arterial concentrations, extraction, and extraction ratios of most of the substrates measured. The small increase in the arterial concentration of free fatty acids is probably related to both the lipoprotein lipase activating action of heparin28 and the effect of fasting before and during the study. The reduction in the extraction ratio of free fatty acids is difficult to interpret. It may be spurious, because the free fatty acid arteriovenous concentration difference was narrow, and therefore small errors in measuring concentrations would have had a large effect upon estimated extraction. Dopexamine was well tolerated by the patients in this study and no arrhythmias were seen. Two patients reported tremor. This symptom has been described in similar groups of patients treated with beta adrenergic agonist drugs.2930 At the high dose level two of the patients with severe coronary artery disease experienced mild chest pain typical of angina pectoris at a time when both had substantial increases in heart rate ( > 30%). One of these patients was a net myocardial producer of lactate at rest (extraction ratio -23%) and remained so at the high dose (extraction ratio -6%). The second patient was a myocardial extractor of lactate at rest, and the onset of chest pain was associated with evidence suggesting a switch to anaerobic myocardial metabolism (extraction ratio -12%). In neither of these two patients was the increase in myocardial oxygen consumption (417 and 2 3 ml/min) at the high dose greater than in the group mean (6-5 ml/min) nor was the onset of chest pain associated with the development of electrocardiographic manifestations of myocardial ischaemia.
The study results indicate that dopexamine has many beneficial haemodynamic properties in patients with heart failure, although its positive chronotropic action may limit its use in patients with coronary artery disease in whom the relation between myocardial supply and demand may be precarious. The precise mode of action of the drug is uncertain but improved cardiac performance is probably due principally to its peripheral vasodilator properties, although it may also have a positive inotropic effect. Further clinical evaluation is required, particularly an assessment of the efficacy of dopexamine in the setting of acute pump failure and a direct comparison of its actions with those of dopamine.
